(Q48342095)

English

[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies

scientific article published on 10 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

0 references

normal pressure hydrocephalus

1 reference

based on heuristic

inferred from title

object named as

Adrian Smith

7

0 references

Steven E. Arnold

5

object named as

Steven E Arnold

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

1

object named as

Juha O Rinne

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

author name string

Dean F Wong

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

David A Wolk

3

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

Ville Leinonen

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

Chris Buckley

6

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

Richard McLain

8

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

Paul F Sherwin

9

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

Gill Farrar

10

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

Marita Kailajärvi

11

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

Igor D Grachev

12

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

publication date

10 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

Acta Neuropathologica

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

124

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

6

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

833-845

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

https://scigraph.springernature.com/pub.10.1007/s00401-012-1051-z

0 references

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Frequency of stages of Alzheimer-related lesions in different age categories

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

An evaluation of current methods for the diagnostic histochemistry of amyloid

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Technical aspects of amyloid imaging for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

PET imaging of amyloid deposition in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Amyloid peptides and proteins in review

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Post-mortem findings in 10 patients with presumed normal-pressure hydrocephalus and review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

The CERAD Neuropsychologic Battery Total Score and the progression of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Imaging beta-amyloid burden in aging and dementia.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

PET of brain amyloid and tau in mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Update on amyloid imaging: from healthy aging to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Amyloid imaging in mild cognitive impairment subtypes.

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Amyloid imaging: from benchtop to bedside

1 reference

https://api.crossref.org/works/10.1007%2FS00401-012-1051-Z

21 January 2018

Identifiers

10.1007/S00401-012-1051-Z

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23053137

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48342095&oldid=2195592271"